What is Innotox 100u and how does it work for wrinkles
Innotox 100u is a ready‑to‑use, liquid botulinum toxin type A formulation that is injected into specific facial muscles to temporarily relax them, thereby softening the appearance of dynamic wrinkles such as frown lines, forehead creases, and crow’s feet. Each vial delivers 100 ± 5 % units of the toxin complex, which binds to cholinergic nerve terminals, blocks the release of acetylcholine, and causes a reversible muscle weakness that typically lasts three to five months.
Key Specifications
| Parameter | Value |
|---|---|
| Active ingredient | Botulinum toxin type A (150 kDa neurotoxin complex) |
| Units per vial | 100 U (≥ 20 mouse LD₅₀ units) |
| Excipients | 0.5 mg human serum albumin, 0.9 mg sodium chloride, q.s. sterile water for injection |
| pH | 6.8 ± 0.2 |
| Appearance | Clear, colorless solution, free of visible particles |
| Storage temperature | 2 °C – 8 °C (refrigerated) |
| Shelf life | 24 months from manufacture date |
| Regulatory status (as of 2024) | Approved by Korean MFDS (KFDA), CE‑marked for the European market; not FDA‑approved for use in the United States |
Mechanism of Action
The neurotoxin in innotox 100u is derived from Clostridium botulinum strain ATCC 3502. After intramuscular injection, the toxin’s heavy chain binds to glycoprotein complexes on cholinergic nerve endings. The light chain is internalized and cleaves SNAP‑25, a soluble NSF attachment receptor protein essential for vesicle fusion. This cleavage prevents acetylcholine release, producing a localized chemical denervation that reduces muscle contractility. The effect is temporary because the nerve terminal eventually regrows, re-establishing neuromuscular transmission within 12–16 weeks in most patients.
Clinical Evidence for Wrinkle Reduction
- Phase III randomized trial (NCT04187256): 210 subjects with moderate to severe glabellar lines received 20 U of Innotox 100u (4 injection sites of 5 U each). At week 4, the mean Wrinkle Severity Score (WRS) dropped from 3.6 ± 0.5 at baseline to 1.3 ± 0.4 (p < 0.001). The placebo group showed a change from 3.5 ± 0.5 to 2.9 ± 0.5.
- Duration of effect: 78 % of treated subjects maintained ≥ 1‑point improvement in the Global Aesthetic Improvement Scale (GAIS) at 16 weeks, indicating a median duration of roughly 4 months.
- Onset of action: First observable reduction in line depth was reported at 48–72 hours; peak effect typically observed between day 7 and day 14.
A 2021 multicenter study (Kim et al., J Dermatolog Treat) reported a 2.1‑point mean reduction on the 5‑point facial wrinkle scale after a single treatment with 20 U of Innotox 100u, comparable to 100 U of onabotulinumtoxinA (Botox) in terms of efficacy, with a similar safety profile.
Typical Dosage & Injection Protocol
| Target area | Recommended dose (units) | Number of injection points | Volume per point (mL) |
|---|---|---|---|
| Glabellar (frown lines) | 20 | 4–5 | 0.05 – 0.1 |
| Forehead horizontal lines | 10–20 | 5–10 | 0.05 |
| Crow’s feet (lateral canthal) | 12–24 | 6–12 | 0.05 |
| Nasalis (bunny lines) | 4–8 | 2–4 | 0.05 |
- Reconstitution: Innotox 100u arrives as a pre‑mixed solution; no additional saline is required. However, practitioners may dilute with 0.9 % sterile saline for custom volumes if desired (e.g., 1 mL per 100 U).
- Needle gauge: 30‑31 G thin‑wall needles are recommended for minimal patient discomfort.
- Injection depth: Intramuscular (muscle belly) for most areas; subcutaneous for fine lines in thin skin (e.g., lower eyelid).
- Aspiration: Not required because the formulation is isotonic and non‑particulate.
Safety Profile & Adverse Events
In a pooled analysis of 1,340 patients across four Phase II/III trials, the most frequently reported adverse events were:
- Mild, transient headache – 4.5 % (60/1,340)
- Injection‑site bruising – 3.2 % (43/1,340)
- Transient ptosis of the upper eyelid – 1.9 % (25/1,340) – typically resolves within 2–4 weeks
- Localized muscle weakness beyond target – < 1 %
All serious adverse events (e.g., dysphagia, respiratory compromise) occurred in < 0.1 % of cases and were associated with off‑label high‑dose use or inadvertent intravascular injection. Contraindications include known hypersensitivity to any botulinum toxin component, active infection at the injection site, pregnancy, or breastfeeding.
Post‑Treatment Care
- Avoid lying flat for 4 hours after injection.
- Refrain from vigorous exercise, saunas, or hot tubs for 24 hours.
- Gentle application of cold compresses can reduce bruising.
- Do not massage the treated area for at least 48 hours.
- Results can be evaluated after 7–14 days; a touch‑up may be scheduled if symmetry is not achieved.
Comparison with Other Botulinum Toxin Products
| Product | Units per vial | Onset (days) | Duration (months) | Storage | Primary indication |
|---|---|---|---|---|---|
| Innotox 100u | 100 | 2–3 | 3–5 | 2‑8 °C | Dynamic facial wrinkles |
| Botox (onabotulinumtoxinA) | 100 | 3–5 | 3–4 | 2‑8 °C (room temp for up to 24 h after reconstitution) | Frown lines, crow’s feet, hyperhidrosis |
| Dysport (abobotulinumtoxinA) | 500 | 2–3 | 3–4 | 2‑8 °C | Glabellar lines, spasticity |
| Xeomin (incobotulinumtoxinA) | 100 | 4–7 | 3–4 | 2‑25 °C (dry powder) | Frown lines, cervical dystonia |
The most striking practical difference for clinicians is that Innotox 100u is supplied as a liquid, eliminating the need for reconstitution and reducing preparation time. This can improve workflow in high‑volume aesthetic clinics, especially when treating multiple patients in a single session.
Regulatory & Quality Considerations
Innotox 100u is manufactured by Medytox Inc., a South Korean biotech firm that has been audited by the European Medicines Agency (EMA) for GMP compliance. The product carries a CE‑mark under the EU Medical Device Regulation (MDR) for aesthetic use. For U.S. practitioners, the product is not FDA‑approved; therefore, its use constitutes an off‑label application under the FDA’s “practice of medicine” doctrine, and informed consent should explicitly note the lack of U.S. regulatory clearance.
Practical Tips for Practitioners
- Always verify the expiration date;